Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Laboratory), Therapeutic Area (Oncology, Infectious Disease), Molecule Type (Vaccine, CGT), End User (Pharma, Biopharma, Research Institute) - Global Forecast to 2026
[389 Pages Report] The contract research organization (CRO) services market is projected to reach USD 86.5 billion by 2026 from USD 53.2 billion in 2021, at a CAGR of 10.7% during the forecast period. Growth in the contract research organization (CRO) services market can mainly be attributed to factors such as increasing investment in pharmaceutical R&D to drive CROs services market, increasing number of clinical trials, and rising prevalence of orphan and rare diseases.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on the Global Contract Research Organization (CRO) Services Market
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from being a regional crisis to a global pandemic. The COVID-19 pandemic has increased the burden on healthcare systems across the globe. According to the WHO, there were 177,108,695 confirmed cases of COVID-19, including 3,840,223 deaths (as of June 18, 2021). The highest number of deaths was in the Americas, followed by Europe and Southeast Asia.
With the World Health Organization (WHO) officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies have scaled up R&D and manufacturing efforts to develop and distribute test kits, vaccines and drugs against the SARS-CoV-2 virus. To expedite the R&D process, many pharmaceutical and biotechnology companies teamed up with CROs through long-term agreements, partnerships, and collaborations across the globe. Also, CROs have developed dedicated services for COVID-19 research. In 2020, there have been number of new service launches and agreements, partnerships, collaborations with different pharmaceutical companies and academic institutes for the research & development of COVID-19 vaccines, drugs & diagnostics across the globe has been recorded. For instance, in October 2020, Parexel’s Biotech division entered into a strategic collaboration with Synairgen plc (UK) to conduct a pivotal phase III study of an interferon beta (IFN-beta) treatment for patients hospitalized with COVID-19.
Contract research organization (CRO) services mARKET dynamics
Driver: Increasing investment in pharmaceutical R&D to drive the CROs services market
Most pharmaceutical, biopharmaceutical, and medical device companies continue to invest heavily in the development of novel drugs and devices. The pharmaceutical industry, in particular, is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. The trend suggests that the top pharma companies are increasing their R&D efficiencies through heavy investments in R&D to see return on their investment in the longer term and through collaborative R&D efforts. According to EvaluatePharma report, the worldwide pharmaceutical R&D spending was valued at USD 136 billion in 2012; this increased to USD 186 billion in 2019.
Challenges: Shortage of skilled professionals
CROs face challenges in attracting and retaining highly skilled professionals as they compete with pharmaceutical, biotechnology, and medical device companies as well as academic and research institutions for qualified and experienced scientists. To compete effectively, companies have to offer higher compensations and other benefits; this may affect the finances and results of operations of players, especially small-scale analytical testing providers. This shortage of skilled professionals may hamper the adoption of new technologies and methodologies, and inhibit the growth of the CRO services market in the coming years
Opportunity: Growth in the drugs and biologics market, despite of COVID pandemic
Despite of ongoing Covid-19 pandemic in 2020, the pharmaceutical industry has been the second-best year in terms of the number of drugs approved by the US FDA. This year witnessed the authorization of 53 drugs—a number surpassed only in 2018 with 59 pharmaceutical agents. The 53 approvals in 2020 include 40 new chemical entities and 13 biologics which comprised of 10 monoclonal antibodies, 2 antibody–drug conjugates, 3 peptides, and 2 oligonucleotides. The FDA has authorized 160 drugs in the last three years (2018–2020), compared to the approval of only 21 drugs in 2010. This growth in the number of approved products worldwide is attributed to the growing investments by biopharmaceutical companies in order to develop biologics and biosimilar.
By type, the clinical research services segment accounted for the largest share of the contract research organization (CRO) services market in 2020.
On the basis of type, the CRO services market is segmented into early-phase services, clinical research services, laboratory services, consulting services, and data management services. The clinical research services dominated the market in 2020. The large share of this segment can be attributed to rapid growth in the geriatric population, subsequent increase in the prevalence of chronic diseases, and rising demand for newer drugs.
By therapeutic area, oncology segment accounted for the largest share of the contract research organization (CRO) services market in 2020.
Based on therapeutic area, the global CRO services market is broadly categorized into oncology, infectious diseases, neurology, cardiovascular system (CVS) disorders metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. The oncology is the largest segment in the CRO services market, which is attributed to the high incidence of cancer and pipeline of drugs in late-stage development.
By molecule type, cell and gene therapy segment is projected to register the highest CAGR during the forecast period
- Based on molecule type, the global CRO services market is segmented into vaccines, cell & gene therapy and other molecules. The cell & gen therapy segment is expected to register the highest CAGR during the forecast period owing to promising therapies in pipeline and rising R&D expenditure in regenerative medicine.
By end user, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the contract research organization (CRO) services market in 2020.
Based on end user, the global CRO services market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. In 2020, the pharmaceutical & biopharmaceutical companies dominated the market owing to increased outsourcing of early-phase development services and clinical and laboratory testing services by pharmaceutical companies.
North America accounted for the largest share of the contract research organization (CRO) services market in 2020.
In 2020, North America accounted for the largest share of the contract research organization (CRO) services market, followed by Europe. The large share of the North American regional segment can be attributed to presence of a well-established base of pharmaceutical & biopharmaceutical companies, and high investments in the biosimilars & biologics segment.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), PPD (US), and ICON Plc (US) are the prominent players operating in the contract research organization (CRO) services market.
Scope of the report
|
Report Metric |
Details |
|
Market Size Available for Years |
2019–2026 |
|
Base Year Considered |
2020 |
|
Forecast Period |
2021–2026 |
|
Forecast Units |
Value (USD Billion) |
|
Segments Covered |
Type, Therapeutic Area, Molecule Type, End User and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, Latin America and Middle East & Africa |
|
Companies Covered |
The major market players include including IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), Parexel International (US), PPD (US), ICON Plc (US), Medpace Holdings (US), SGS (Switzerland), PSI CRO AG (US), Axcent Advanced Analytics (US), BIO Agile Therapeutics (US), Firma Clinical Research (US), Acculab Life Sciences (US), Azelix (US), CTserv (US), Pepgra (UK), and Dove Quality Solutions (US), Novotech Health Holding (Australia), Geneticist Inc. (US), Linical Americas (US), Frontage Holding Corporation (US), and Celerion (US). |
The study categorizes the contract research organization (CRO) services market into the following segments and subsegments:
By Type
- Early Phase Development Services
- Chemistry, Manufacturing & Control
- Preclinical Services
- Pharmacokinetics/Pharmacodynamics (PK/PD)
- Toxicology Testing
- Other Preclinical Services
- Discovery Studies
- Clinical Research Services
- Phase I
- Phase II
- Phase III
- Phase IV
- Laboratory Services
- Bioanalytical Testing
- Analytical Testing
- Physical Characterization
- Raw Material Testing
- Batch Release Testing
- Stability Testing
- Other Analytical Testing
- Consulting Services
- Data Management Services
By Therapeutic Area
- Oncology
- Infectious Diseases
- Neurology
- CVS
- Metabolic Disorders/Endocrinology
- Immunological Disorders
- Respiratory Disorders
- Psychiatry
- Dermatology
- Hematology
- Ophthalmology
- Gastrointestinal
- Genitourinary & Women’s Health
- Other Therapeutic Areas
By Molecule Type
- Vaccines
- Cell and Gene Therapy Diseases
- Other Molecule Types
By End User
- Pharmaceutical & Biotechnology Companies
- Medical Device Companies
- Academic Institutes
By Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- The Middle East and Africa
Recent Developments
- In April 2021, IQVIA acquired Q2 Solutions, a clinical laboratory services organization, from Quest Diagnostics.
- In November 2020, WuXi Apptec expanded its Cell & Gene Therapy Platforms with capabilities to provide high-quality and cost-effective supplies of R&D and GMP Plasmids
- In April 2020, IQVIA launched COVID-19 trial matching service to accelerate treatment and vaccine development against the COVID-19 pandemic in U.S. The company launched comprehensive online screener and trial matching tool for all COVID-19 trials in the US.
- In May 2020, IQVIA announced the Japan and Asia Pacific expansion of IQVIA Biotech to deliver integrated clinical & commercial solutions and support biotech and emerging biopharma companies.
Frequently Asked Questions (FAQ):
What is the current size of the global contract research organization (CRO) services market?
The contract research organization (CRO) services market is projected to reach USD 86.5 billion by 2026 from USD 53.2 billion in 2021, at a CAGR of 10.7% during the forecast period.
Who are the leading players in the contract research organization (CRO) services market?
Some of the leading players in the contract research organization (CRO) services market include are IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), PPD (US), and ICON Plc (US).
What are the major therapeutic area of the contract research organization (CRO) services market?
The application of the contract research organization (CRO) services market is segmented into oncology, infectious diseases, neurology, cardiovascular system (CVS) disorders metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. Oncology is the largest segment in the CRO services market in 2020.
What are the major drivers of the contract research organization (CRO) services market?
Some of the major drivers of the contract research organization (CRO) services market includes rising investment in pharmaceutical R&D to drive CROs services market, increasing number of clinical trials and rising prevalence of orphan and rare diseases. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 48)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 CRO SERVICES MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 53)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 64)
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021 VS. 2026 (USD MILLION)
FIGURE 14 CRO SERVICES MARKET, BY MOLECULE TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 15 CRO SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET
4 PREMIUM INSIGHTS (Page No. - 68)
4.1 CRO SERVICES MARKET OVERVIEW
FIGURE 17 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY PRODUCT & COUNTRY (2020)
FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CRO SERVICES MARKET IN 2020
4.3 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 19 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2026
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2020
FIGURE 20 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2020
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN CRO SERVICES MARKET FROM 2021 TO 2026
5 MARKET OVERVIEW (Page No. - 72)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Increasing investment in pharmaceutical R&D
FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2016
FIGURE 24 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021
5.2.1.2 Rising number of clinical trials creates significant demand for CRO services
FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021)
5.2.1.3 High cost of in-house drug development encourages pharma biotech companies to outsource contract R&D services
FIGURE 26 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
5.2.1.4 Rising prevalence of orphan and rare diseases creates new revenue pockets for CROs
5.2.2 OPPORTUNITIES
5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic
FIGURE 27 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020)
TABLE 2 LIST OF BIOLOGICS APPROVALS BY US FDA, 2020
5.2.2.2 Rising demand for specialized testing services among end users
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals for clinical trials
5.2.3.2 Requirement for unique analytical testing approach for innovative formation
5.2.4 MARKET TRENDS
5.2.4.1 Revolutionary shift in CRO services market due to growing adoption of artificial intelligence-based tools for drug discovery
5.2.4.2 Increased outsourcing to emerging Asian economies
5.2.4.3 CRO industry consolidation
TABLE 3 LIST OF ACQUISITIONS
5.2.4.4 Integrated end-to-end R&D service solution
5.3 RANGES/SCENARIO
FIGURE 28 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF CRO SERVICES MARKET
5.4 IMPACT OF COVID-19 OUTBREAK ON CRO SERVICES MARKET
FIGURE 29 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 30 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS
5.6 PRICING ANALYSIS
TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020)
5.7 VALUE CHAIN ANALYSIS
FIGURE 31 VALUE CHAIN ANALYSIS OF CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE
5.8 ECOSYSTEM ANALYSIS
FIGURE 32 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET
TABLE 5 SUPPLY CHAIN ECOSYSTEM
5.9 TECHNOLOGY ANALYSIS
5.10 CASE STUDY
5.10.1 COVANCE FSPX DATA ANALYSIS USED TO DETERMINE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIAL
5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR
5.11 REGULATORY ANALYSIS
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 BARGAINING POWER OF SUPPLIERS
5.12.5 DEGREE OF COMPETITION
6 CRO SERVICES MARKET, BY TYPE (Page No. - 98)
6.1 INTRODUCTION
TABLE 7 CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.2 CLINICAL RESEARCH SERVICES
6.2.1 GROWING NUMBER OF CLINICAL TRIALS AND PARTNERSHIPS WITH CROS PROPEL GROWTH OF SEGMENT
TABLE 8 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF JUNE 2021, BY LOCATION
TABLE 9 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
FIGURE 33 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020
TABLE 10 CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 11 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 12 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 13 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.2.2 PHASE III CLINICAL RESEARCH SERVICES
6.2.2.1 Rising cost of Phase III trials and high number of patients recruited in these trials increases demand for cost effective CRO services
TABLE 15 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY
TABLE 16 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 17 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 19 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.2.3 PHASE II CLINICAL RESEARCH SERVICES
6.2.3.1 Long duration of Phase II studies provides growth opportunities for CROs
TABLE 20 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
TABLE 21 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 22 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 23 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 24 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.2.4 PHASE I CLINICAL RESEARCH SERVICES
6.2.4.1 Robust pipeline of pharmaceutical companies drives segment growth
TABLE 25 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES
TABLE 26 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 27 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 29 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.2.5 PHASE IV CLINICAL RESEARCH SERVICES
6.2.5.1 Rising number of CROs providing post-marketing surveillance drives segment growth
TABLE 30 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
TABLE 31 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 32 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 34 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 EARLY-PHASE DEVELOPMENT SERVICES
6.3.1 RISING NEED FOR EARLY-PHASE DEVELOPMENT STUDIES FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH
FIGURE 34 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2019)
TABLE 35 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS
TABLE 36 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 37 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 38 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 39 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.2 CHEMISTRY, MANUFACTURING & CONTROL SERVICES
6.3.2.1 High demand for CMC services to check quality standards of drugs
TABLE 41 CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 42 NORTH AMERICA: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 43 EUROPE: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 44 ASIA PACIFIC: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.3 PRECLINICAL SERVICES
6.3.3.1 Rising demand for preclinical services for PK/PD and toxicology testing propels growth of segment
TABLE 45 PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 46 PRECLINICAL SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 47 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 48 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.4 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES
6.3.4.1 Increasing importance of studies to determine pharmacokinetic behavior of drug candidates to drive segment
TABLE 50 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 51 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 52 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 53 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.5 TOXICOLOGY TESTING SERVICES
TABLE 54 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 55 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 56 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 57 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.6 OTHER PRECLINICAL SERVICES
6.3.6.1 Increasing use of molecular imaging, flow cytometry, and immunohistochemistry to boost segment
TABLE 58 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 59 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 60 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 61 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.7 DISCOVERY STUDIES
6.3.7.1 Rising importance of CRO services for target identification and validation to promote segment growth
TABLE 62 DISCOVERY STUDIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 63 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 64 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 65 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4 LABORATORY SERVICES
6.4.1 INCREASING IMPORTANCE OF LAB SERVICES TO ENSURE REGULATORY COMPLIANCE TO PROPEL SEGMENT GROWTH
TABLE 66 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 67 LAB SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 LAB SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: LAB SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 70 EUROPE: LAB SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 71 ASIA PACIFIC: LAB SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.2 ANALYTICAL TESTING SERVICES
6.4.2.1 Increasing demand for analytical testing for all stages of drug development drive growth of segment
TABLE 72 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 73 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 74 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 75 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 76 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.3 PHYSICAL CHARACTERIZATION
6.4.3.1 Increasing demand for physical characterization to reduce risk of product failure drives segment growth
TABLE 77 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 78 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 79 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 80 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.4 RAW MATERIAL TESTING
6.4.4.1 High demand for testing services to ensure quality and purity of raw materials drives growth of segment
TABLE 81 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 82 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 83 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 84 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.5 BATCH RELEASE TESTING
6.4.5.1 Comprehensive portfolio of batch-release testing services offered by CROs to propel segment growth
TABLE 85 BATCH RELEASE TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 86 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 87 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 88 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.6 STABILITY TESTING
6.4.6.1 Used to ensure long-term quality, safety, and efficacy of pharmaceutical products
TABLE 89 STABILITY TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 90 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 91 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 92 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.7 OTHER ANALYTICAL TESTING
6.4.7.1 Demand for analytical method validation, cleaning validation, and microbial testing to propel segment growth
TABLE 93 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 94 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 95 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 96 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.8 BIOANALYTICAL TESTING SERVICES
6.4.8.1 High demand for bioanalytical testing due to growing use of macromolecules and biosimilars
TABLE 97 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 98 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 99 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 100 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.5 CONSULTING SERVICES
6.5.1 INCREASING ADOPTION OF CONSULTING SERVICES FOR QUALITY ASSURANCE PURPOSES PROPELS SEGMENT GROWTH
TABLE 101 CONSULTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 102 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 103 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 104 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.6 DATA MANAGEMENT SERVICES
6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD
TABLE 105 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 106 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 107 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 108 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 109 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 150)
7.1 INTRODUCTION
TABLE 110 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
7.2 ONCOLOGY
7.2.1 INCREASING NUMBER OF CANCER CASES DRIVES GROWTH OF SEGMENT
FIGURE 35 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020)
FIGURE 36 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS)
TABLE 111 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
TABLE 112 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2019–2026 (USD MILLION)
TABLE 113 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 114 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 115 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 INFECTIOUS DISEASES
7.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES
TABLE 116 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 117 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 118 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 119 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 NEUROLOGY
7.4.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS DRIVES MARKET
TABLE 120 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
TABLE 121 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2019–2026 (USD MILLION)
TABLE 122 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 123 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 124 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 CARDIOVASCULAR SYSTEM DISORDERS
7.5.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
TABLE 125 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
TABLE 126 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 127 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 128 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 129 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 METABOLIC DISORDERS/ENDOCRINOLOGY
7.6.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE MARKET GROWTH
FIGURE 37 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS)
TABLE 130 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2019–2026 (USD MILLION)
TABLE 131 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 132 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 133 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
7.7 IMMUNOLOGICAL DISORDERS
7.7.1 GROWING IMMUNOLOGIAL DRUGS PIPELINE RESULTING IN INCREASE IN OUTSOURCING ACTIVITIES
TABLE 134 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 135 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 136 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 137 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
7.8 RESPIRATORY DISORDERS
7.8.1 INCREASING PREVALENCE OF RESPIRATORY DISEASE TO SUPPORT GROWTH OF SEGMENT
TABLE 138 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020)
TABLE 139 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 140 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 141 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 142 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
7.9 PSYCHIATRY
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH
TABLE 143 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2019–2026 (USD MILLION)
TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 145 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019–2026 (USD MILLION)
7.10 DERMATOLOGY
7.10.1 INCREASING PREVALENCE OF SKIN DISORDERS PROPELS SEGMENT GROWTH
TABLE 147 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020)
TABLE 148 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2019–2026 (USD MILLION)
TABLE 149 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 150 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 151 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
7.11 HEMATOLOGY
7.11.1 DEVELOPMENT OF DRUGS FOR HEMATOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH
TABLE 152 CRO SERVICES MARKET FOR HAEMATOLOGY, BY REGION, 2019–2026 (USD MILLION)
TABLE 153 NORTH AMERICA: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 154 EUROPE: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 155 ASIA PACIFIC: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
7.12 OPHTHALMOLOGY
7.12.1 GROWING NEED FOR OPTHALMOLOGY-RELATED CLINICAL TRIALS
TABLE 156 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2019–2026 (USD MILLION)
TABLE 157 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 158 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 159 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
7.13 GASTROINTESTINAL DISEASES
7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES AND GROWING INVESTMENT IN R&D TO PROPEL MARKET
TABLE 160 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 162 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.14 GENITOURINARY & WOMEN’S HEALTH
7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN DRIVES SEGMENT GROWTH
TABLE 164 CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2019–2026 (USD MILLION)
TABLE 165 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 166 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 167 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD MILLION)
7.15 OTHER THERAPEUTIC AREAS
7.15.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPPORT SEGMENT GROWTH
TABLE 168 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019–2026 (USD MILLION)
TABLE 169 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 170 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 171 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)
8 CRO SERVICES MARKET, BY MOLECULE TYPE (Page No. - 185)
8.1 INTRODUCTION
TABLE 172 CRO SERVICES MARKET, BY MOLECULE TYPE, 2019–2026 (USD MILLION)
8.2 VACCINES
8.2.1 RISING FOCUS ON IMMUNIZATION FOR INFECTIOUS DISEASES FUELING MARKET GROWTH
TABLE 173 COVID-19 VACICNES IN PIPELINE
TABLE 174 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2019–2026 (USD MILLION)
8.3 CELL & GENE THERAPY
8.3.1 INCREASING FUNDING FOR R&D SUPPORTS MARKET GROWTH
8.4 OTHER MOLECULE TYPES
9 CRO SERVICES MARKET, BY END USER (Page No. - 190)
9.1 INTRODUCTION
TABLE 175 CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINE TO DRIVE MARKET GROWTH
FIGURE 38 ANNUAL DRUG APPROVALS BY FDA’S CDER (2009–2018)
FIGURE 39 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011–2018
TABLE 176 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 178 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 MEDICAL DEVICE COMPANIES
9.3.1 INCREASE IN R&D FOR DEVELOPMENT OF ADVANCED MEDICAL DEVICES FUELING MARKET GROWTH
FIGURE 40 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2010–2020)
FIGURE 41 R&D EXPENSES OF LEADING MEDICAL DEVICE COMPANIES (IN USD MILLION), 2020
TABLE 180 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 181 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 182 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 183 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 ACADEMIC INSTITUTES
9.4.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT
TABLE 184 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 185 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 186 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 187 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
10 CRO SERVICES MARKET, BY REGION (Page No. - 202)
10.1 INTRODUCTION
TABLE 188 CRO SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 42 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT
TABLE 189 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 190 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 191 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 192 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 193 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 194 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 196 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 197 NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 Largest CRO services market in North America due to robust clinical trial activities
FIGURE 43 US CONTINUES TO DOMINATE DISTRIBUTION OF R&D COMPANIES BY REGION (2020 VS. 2019)
TABLE 198 US: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 199 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 200 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 201 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 202 US: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 203 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 204 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 205 US: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing number of clinical trials to support market growth
TABLE 206 CANADA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 207 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 208 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 209 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 210 CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 211 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 212 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 213 CANADA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
FIGURE 44 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018)
TABLE 214 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 215 EUROPE: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 216 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 217 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 219 EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 220 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 221 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 222 EUROPE: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Favorable location for clinical trials due to government support and flexible labor laws
TABLE 223 GERMANY: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 224 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 225 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 226 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 227 GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 228 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 229 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 230 GERMANY: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Investment by pharmaceutical sponsors for drug discovery services to support market growth
FIGURE 45 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013–2017 (USD MILLION)
TABLE 231 UK: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 232 UK: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 233 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 234 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 235 UK: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 236 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 237 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 238 UK: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 High number of oncology clinical trials to drive market growth
TABLE 239 FRANCE: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 240 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 241 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 242 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 243 FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 244 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 245 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 246 FRANCE: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Low drug approval time and growing number of clinical trials to drive market growth
TABLE 247 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
TABLE 248 ITALY: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 249 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 250 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 251 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 252 ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 253 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 254 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 255 ITALY: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Short study start-up times and rising R&D expenditure to boost market growth
FIGURE 46 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011–2017
TABLE 256 SPAIN: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 257 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 258 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 259 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 260 SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 261 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 262 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 263 SPAIN: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 264 ROE: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 265 ROE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 266 ROE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 267 ROE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 268 ROE: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 269 ROE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 270 ROE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 271 ROE: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 47 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT
TABLE 272 APAC: CRO SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 273 APAC: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 274 APAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 275 APAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 276 APAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 277 APAC: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 278 APAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 279 APAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 280 APAC: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Dominates market due to robust pharmaceutical industry and presence of prominent CROs
TABLE 281 CHINA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 282 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 283 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 284 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 285 CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 286 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 287 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 288 CHINA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Strong focus on research to drive market growth
TABLE 289 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 290 JAPAN: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 291 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 292 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 293 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 294 JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 295 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 296 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 297 JAPAN: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Growing pharmaceutical industry to drive market growth
TABLE 298 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 299 INDIA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 300 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 301 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 302 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 303 INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 304 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 305 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 306 INDIA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 Favorable location for drug discovery due to large number of research institutes
TABLE 307 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 308 AUSTRALIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 309 AUSTRALIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 310 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 311 AUSTRALIA: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 312 AUSTRALIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 313 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 314 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Government initiatives and growing R&D activities for drug development to drive market growth
TABLE 315 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 316 SOUTH KOREA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 317 SOUTH KOREA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 318 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 319 SOUTH KOREA: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 320 SOUTH KOREA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 321 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 322 SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 323 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 324 ROAPAC: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 325 ROAPAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 326 ROAPAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 327 ROAPAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 328 ROAPAC: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 329 ROAPAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 330 ROAPAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 331 ROAPAC: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 GROWING R&D EXPENDITURE IN PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH
TABLE 332 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 333 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 334 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 335 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 336 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 337 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 338 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 339 LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
TABLE 340 MEA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 341 MEA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION)
TABLE 342 MEA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 343 MEA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 344 MEA: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 345 MEA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 346 MEA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
TABLE 347 MEA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 277)
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 48 CRO SERVICES MARKET: STRATEGIES ADOPTED
11.3 REVENUE ANALYSIS
FIGURE 49 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST THREE YEARS
11.4 MARKET SHARE ANALYSIS
FIGURE 50 CRO SERVICES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
11.5 COMPANY EVALUATION QUADRANT
FIGURE 51 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX, 2020
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
FIGURE 52 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2020
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
11.7 COMPETITIVE BENCHMARKING
11.7.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
FIGURE 53 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
11.7.2 COMPANY INDUSTRY FOOTPRINT (20 COMPANIES)
TABLE 348 INDUSTRY FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
11.7.3 COMPANY SERVICE OFFERING FOOTPRINT (20 COMPANIES)
TABLE 349 SERVICE OFFERING FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
11.7.4 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
TABLE 350 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
11.8 COMPETITIVE SCENARIO AND TRENDS
11.8.1 SERVICES LAUNCHES
TABLE 351 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2017-NOVEMBER 2020
11.8.2 DEALS
TABLE 352 CRO SERVICES MARKET: DEALS, JANUARY 2017-NOVEMBER 2020
11.8.3 OTHER DEVELOPMENTS
TABLE 353 CRO SERVICES MARKET: EXPANSION, JANUARY 2017-NOVEMBER 2020
12 COMPANY PROFILES (Page No. - 293)
12.1 KEY COMPANIES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 IQVIA
TABLE 354 IQVIA: BUSINESS OVERVIEW
FIGURE 54 IQVIA: COMPANY SNAPSHOT
TABLE 355 IQVIA: SERVICE OFFERINGS
TABLE 356 IQVIA: SERVICE LAUNCHES
TABLE 357 IQVIA: DEALS
TABLE 358 IQVIA: EXPANSION
12.1.2 LABCORP
TABLE 359 LABCORP: BUSINESS OVERVIEW
FIGURE 55 LABCORP: COMPANY SNAPSHOT
TABLE 360 LABCORP: SERVICE OFFERINGS
TABLE 361 LABCORP: SERVICE LAUNCHES
TABLE 362 LABCORP: DEALS
TABLE 363 LABCORP: EXPANSION
12.1.3 SYNEOS HEALTH INC.
TABLE 364 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
FIGURE 56 SYNEOS HEALTH INC.: COMPANY SNAPSHOT
TABLE 365 SYNEOS HEALTH INC.: SERVICE OFFERINGS
TABLE 366 SYNEOS HEALTH INC: SERVICE LAUNCHES
TABLE 367 SYNEOS HEALTH INC.: DEALS
12.1.4 WUXI APPTEC
TABLE 368 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 57 WUXI APPTEC: COMPANY SNAPSHOT
TABLE 369 WUXI APPTEC : SERVICE OFFERINGS
TABLE 370 WUXI APPTEC: SERVICE LAUNCHES
TABLE 371 WUXI APPTEC: DEALS
TABLE 372 WUXI APPTEC: EXPANSION
12.1.5 CHARLES RIVER LABORATORIES
TABLE 373 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 58 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 374 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS
TABLE 375 CHARLES RIVER LABORATORIES: DEALS
TABLE 376 CHARLES RIVER LABORATORIES: EXPANSION
12.1.6 PAREXEL INTERNATIONAL
TABLE 377 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW
TABLE 378 PAREXEL INTERNATIONAL: SERVICE OFFERINGS
TABLE 379 PAREXEL INTERNATIONAL: SERVICE LAUNCHES
TABLE 380 PAREXEL INTERNATIONAL: DEALS
TABLE 381 PAREXEL INTERNATIONAL: EXPANSION
12.1.7 PRA HEALTH SCIENCES
TABLE 382 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
FIGURE 59 PRA HEALTH SCIENCES: COMPANY SNAPSHOT
TABLE 383 PRA HEALTH SCIENCES: SERVICE OFFERINGS
TABLE 384 PRA HEALTH SCIENCES: SERVICE LAUNCHES
TABLE 385 PRA HEALTH SCIENCES: DEALS
TABLE 386 PRA HEALTH SCIENCES: EXPANSION
12.1.8 PPD INC
TABLE 387 PPD INC: BUSINESS OVERVIEW
FIGURE 60 PPD INC: COMPANY SNAPSHOT
TABLE 388 PPD INC: SERVICE OFFERINGS
TABLE 389 PPD: SERVICE LAUNCHES
TABLE 390 PPD: DEALS
TABLE 391 PPD: EXPANSION
12.1.9 ICON PLC
TABLE 392 ICON PLC: BUSINESS OVERVIEW
FIGURE 61 ICON PLC: COMPANY SNAPSHOT
TABLE 393 ICON PLC: SERVICE OFFERINGS
TABLE 394 ICON PLC : SERVICE LAUNCHES
TABLE 395 ICON PLC: DEALS
12.1.10 MEDPACE HOLDINGS INC
TABLE 396 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW
FIGURE 62 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT
TABLE 397 MEDPACE HOLDINGS INC: SERVICE OFFERINGS
TABLE 398 MEDPACE HOLDINGS INC: DEALS
TABLE 399 MEDPACE HOLDINGS INC: EXPANSION
12.1.11 SGS
TABLE 400 SGS: BUSINESS OVERVIEW
FIGURE 63 SGS: COMPANY SNAPSHOT
TABLE 401 SGS: SERVICE OFFERINGS
TABLE 402 SGS: DEALS
12.1.12 FRONTAGE HOLDINGS CORPORATION
TABLE 403 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 64 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT
TABLE 404 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS
TABLE 405 FRONTAGE HOLDINGS CORPORATION: DEALS
TABLE 406 FRONTAGE HOLDINGS CORPORATION: EXPANSION
12.1.13 PSI CRO AG
TABLE 407 PSI CRO AG: BUSINESS OVERVIEW
TABLE 408 PSI CRO AG: SERVICE OFFERINGS
TABLE 409 PSI CRO AG: EXPANSION
12.1.14 BIO AGILE THERAPEUTICS
TABLE 410 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW
TABLE 411 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS
12.1.15 FIRMA CLINICAL RESEARCH
TABLE 412 FIRMA CLINICAL RESEARCH: BUSINESS OVERVIEW
TABLE 413 FIRMA CLINICAL RESEARCH: SERVICE OFFERINGS
12.1.16 ACCULAB LIFE SCIENCES
TABLE 414 ACCULAB LIFE SCIENCES: BUSINESS OVERVIEW
TABLE 415 ACCULAB LIFE SCIENCES: SERVICE OFFERINGS
12.1.17 NOVOTECH HEALTH HOLDINGS
TABLE 416 NOVOTECH HEALTH HOLDINGS: BUSINESS OVERVIEW
TABLE 417 NOVOTECH HEALTH HOLDINGS: SERVICE OFFERINGS
TABLE 418 NOVOTECH HEALTH HOLDINGS: DEALS
12.1.18 GENETICIST INC.
TABLE 419 GENETICIST INC.: BUSINESS OVERVIEW
TABLE 420 GENETICIST INC.: SERVICE OFFERINGS
12.1.19 LINICAL AMERICAS
TABLE 421 LINICAL AMERICAS: BUSINESS OVERVIEW
TABLE 422 LINICAL AMERICAS: SERVICE OFFERINGS
TABLE 423 LINICAL AMERICAS: DEALS
12.1.20 CELERION
TABLE 424 CELERION.: BUSINESS OVERVIEW
TABLE 425 CELERION.: SERVICE OFFERINGS
TABLE 426 CELERION.: SERVICE LAUNCHES
12.2 OTHER PLAYERS
12.2.1 AZELIX
TABLE 427 AZELIX: COMPANY OVERVIEW
12.2.2 CTSERV
TABLE 428 CTSERV: COMPANY OVERVIEW
12.2.3 PEPGRA
TABLE 429 PEPGRA: COMPANY OVERVIEW
12.2.4 AXCENT ADVANCED ANALYTICS (A3)
TABLE 430 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW
12.2.5 DOVE QUALITY SOLUTIONS
TABLE 431 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 381)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global contract research organization (CRO) services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the contract research organization (CRO) services market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Secondary Data
The secondary sources referred to for this research study include publications from government sources, such as the Association of Clinical Research Organization (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICRO), Clinical and Contract Research Association (CCRA), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan CRO Association, Chinese Association for Laboratory Animal Sciences (CALAS), and Indian Society for Clinical Research. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global CRO services market, which was validated through primary research.
Primary Data
Extensive primary research was conducted after acquiring basic knowledge about the global contract research organization (CRO) services market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies and academic institutes) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others from tier 1 and tier 2 companies engaged in offering product in contract research organization (CRO) services market) across five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Primary research was used in this report to:
- Validate the market segmentation defined through a product and service portfolio assessment of the leading players in the CRO services market
- Understand key industry trends and issues defining the strategic growth objectives of market players
- Gather both demand- and supply-side validation of the key factors affecting the market growth (such as market drivers, challenges, and opportunities)
- Validate assumptions for the market sizing and forecasting model used for this study
- Understand the market position of leading players in the CRO services market and their market shares/rankings
To know about the assumptions considered for the study, download the pdf brochure
Data Triangulation
After arriving at the overall market size, from the market size estimation process explained above, the contract research organization (CRO) services market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the contract research organization (CRO) services market
Report Objectives
- To define, describe, and forecast the global contract research organization (CRO) services market based on type, therapeutic area, molecule type, end user, and region.
- To provide detailed information on the major factors influencing the market growth (such as drivers, challenges, and opportunities).
- To strategically analyze micromarkets in terms of individual growth trends, future prospects, and contributions to the overall contract research organization (CRO) services market.
- To analyze opportunities in the global market for major stakeholders and provide a detailed competitive landscape for market leaders.
- To forecast the size of the market segments with respect to five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
- To profile the key players and comprehensively analyze their market shares and core competencies.
- To track and analyze competitive developments such as new service launches; acquisitions; expansions; and partnerships, collaborations, and agreements
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the rest of Europe CRO services market, by country
- Further breakdown of the rest of Asia Pacific CRO services market, by country
- Further breakdown of the Latin American and Middle Eastern & African CRO services market, by country
Company Information
Detailed analysis and profiling of additional market players (up to 5) inclusive of:
- Business Overview
- Financial Information
- Product Offered
- Developments (Last three years)
Get in-depth analysis of the COVID-19 impact on the Contract Research Organization (CROs) Services Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Contract Research Organization (CROs) Services Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Contract Research Organization (CROs) Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Contract Research Organization (CROs) Services Market